How India Exports Vaccine to the World

In the United States, vaccines are regulated as biological products under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act. Unlike small-molecule drugs, vaccines are not approved through Abbreviated New Drug Applications (ANDAs) and are therefore not listed in the FDA's Orange Book. Instead, they undergo a rigorous Biologics License Application (BLA) process, which includes comprehensive evaluations of safety, efficacy, and manufacturing quality. The FDA's Center for Biologics Evaluation and Research (CBER) oversees this process, ensuring that all vaccines meet stringent regulatory standards before entering the U.S. market. Given the complexity and variability of vaccine formulations, the BLA pathway is essential for maintaining public health and safety.

For Indian vaccine manufacturers aiming to enter the U.S. market, understanding the BLA process is crucial. This involves detailed submissions of clinical trial data, manufacturing protocols, and quality control measures. Additionally, compliance with the FDA's Good Manufacturing Practice (GMP) regulations is mandatory. The absence of ANDA pathways for vaccines underscores the importance of thorough preparation and adherence to regulatory requirements for successful market entry.

In the European Union (EU) and the United Kingdom (UK), vaccines are subject to centralized marketing authorization procedures. The European Medicines Agency (EMA) evaluates applications through the Committee for Medicinal Products for Human Use (CHMP), providing a scientific opinion that forms the basis for the European Commission's final decision. This centralized process ensures uniformity in vaccine approval across EU member states. Similarly, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) conducts independent assessments to grant marketing authorizations within the UK.

Compliance with EU Good Manufacturing Practice (GMP) guidelines is mandatory for vaccine manufacturers. These guidelines encompass all aspects of production, from raw material sourcing to final product release, ensuring consistent quality and safety. Manufacturers must also adhere to the Vaccine Antigen Master File (VAMF) certification system, which centralizes the assessment of vaccine antigens used in multiple products. This system streamlines regulatory processes and maintains high standards across the industry.

The World Health Organization (WHO) includes various vaccines in its Model List of Essential Medicines, recognizing their critical role in public health. Inclusion in this list signifies a vaccine's importance in addressing global health needs. Additionally, the WHO Prequalification Programme assesses vaccines for quality, safety, and efficacy, facilitating their procurement by UN agencies and member states. This program is instrumental in ensuring that vaccines meet international standards and are accessible to populations worldwide.

Vaccine manufacturers must also comply with pharmacopoeial standards, such as those outlined in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). These standards provide detailed specifications for vaccine components, manufacturing processes, and quality control measures, ensuring consistency and safety across different markets.

In India, vaccines are classified under Schedule C of the Drugs and Cosmetics Act, 1940, which pertains to biological and special products. This classification subjects vaccines to specific regulatory requirements, including licensing, manufacturing practices, and quality control measures. The Central Drugs Standard Control Organization (CDSCO) oversees the approval and regulation of vaccines, ensuring they meet national standards for safety and efficacy.

The National Pharmaceutical Pricing Authority (NPPA) monitors vaccine pricing to ensure affordability and accessibility. While vaccines are generally exempt from price control under the Drug Price Control Order (DPCO), the NPPA can intervene if necessary to prevent exorbitant pricing. For exports, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), confirming compliance with national regulations and facilitating international trade.

The patent landscape for vaccines is complex, with numerous patents covering various aspects such as formulations, manufacturing processes, and delivery methods. Unlike small-molecule drugs, vaccines often involve proprietary technologies and biological materials, making generic competition less straightforward. However, as patents expire, opportunities for biosimilar or generic versions may arise, provided they meet stringent regulatory requirements for safety and efficacy.

In August 2025, the WHO updated its Model List of Essential Medicines to include new vaccines targeting emerging infectious diseases, reflecting the evolving global health landscape. This inclusion underscores the importance of these vaccines in addressing public health challenges and encourages their widespread adoption.

In November 2025, the EMA introduced revised guidelines for the Vaccine Antigen Master File (VAMF) certification system, aiming to streamline the approval process for vaccines containing multiple antigens. These revisions are expected to reduce administrative burdens and expedite the availability of complex vaccines in the EU market.

In January 2026, the CDSCO implemented new regulations requiring enhanced pharmacovigilance reporting for vaccine manufacturers, emphasizing the importance of monitoring adverse events post-licensure. This initiative aims to strengthen the safety profile of vaccines and maintain public trust in immunization programs.

In March 2026, the FDA announced the approval of a novel vaccine developed using mRNA technology, marking a significant advancement in vaccine development. This approval highlights the potential of innovative platforms to address unmet medical needs and sets a precedent for future vaccine approvals.

In May 2026, the NPPA conducted a review of vaccine pricing in India, ensuring that essential vaccines remain affordable and accessible to the population. This review reflects the government's commitment to public health and the importance of vaccines in disease prevention.

These developments indicate a dynamic regulatory environment, with ongoing efforts to enhance vaccine accessibility, safety, and innovation globally.

India's vaccine manufacturing sector is heavily reliant on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. This dependency is particularly pronounced in the production of antibiotics, where China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply. Such reliance exposes India's vaccine supply chain to significant risks, including potential disruptions due to geopolitical tensions, trade restrictions, or environmental policies affecting Chinese production.

In response to these vulnerabilities, the Indian government launched the Production Linked Incentive (PLI) scheme in February 2021, aiming to bolster domestic production of APIs and KSMs. By November 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and 6-Aminopenicillanic acid (6-APA), essential for antibiotic production. These initiatives are expected to reduce India's import dependence on key pharmaceutical ingredients by half. However, the effectiveness of these measures in mitigating supply chain risks remains to be fully realized.

Our proprietary trade data indicates a high concentration among Indian vaccine exporters, with the top five companies accounting for 82.0% of total exports. Notably, the Serum Institute of India Private Limited alone holds a 30.2% share, amounting to $314.8 million USD. This concentration poses a single-source risk, as any operational disruptions within these key suppliers could significantly impact global vaccine availability.

The PLI scheme has made strides in diversifying the supplier base. By January 2026, it had attracted investments worth ₹40,294 crore, supporting over 350 manufacturing units, including 28 greenfield facilities. Notably, 191 APIs, KSMs, and drug intermediates were manufactured domestically for the first time under this initiative. While these developments are promising, the vaccine export sector's supplier concentration remains a critical risk factor.

Geopolitical tensions and shipping disruptions pose significant risks to India's vaccine export supply chain. The Red Sea and the Strait of Hormuz are vital maritime routes for Indian exports; any instability in these regions can lead to delays and increased shipping costs. Additionally, escalating U.S.-China tensions have the potential to disrupt the supply of essential raw materials and APIs, given India's reliance on Chinese imports.

Regulatory bodies like the FDA and EMA have issued shortage alerts in recent years, highlighting the fragility of global pharmaceutical supply chains. For instance, in October 2025, the FDA reported shortages of critical antibiotics due to supply chain disruptions. Such incidents underscore the need for robust risk mitigation strategies to ensure uninterrupted vaccine exports.

• Diversify API and KSM Sources: Expand sourcing beyond China by developing partnerships with alternative suppliers in regions like Eastern Europe and Mexico to reduce dependency and enhance supply chain resilience.

• Strengthen Domestic Manufacturing: Accelerate the implementation of the PLI scheme to boost domestic production of critical APIs and KSMs, thereby decreasing reliance on imports.

• Enhance Supplier Base: Encourage the growth of small and medium-sized enterprises (SMEs) in vaccine manufacturing to reduce supplier concentration and mitigate single-source risks.

• Develop Contingency Plans: Establish comprehensive contingency plans to address potential geopolitical and shipping disruptions, including alternative shipping routes and strategic stockpiling of essential materials.

• Monitor Regulatory Alerts: Implement a proactive monitoring system for regulatory shortage alerts from bodies like the FDA and EMA to anticipate and address potential supply chain issues promptly.

RISK_LEVEL: MEDIUM